Skip to main content
Top

01-03-2018 | Original Article

Secular trends in the appropriateness of empirical antibiotic treatment in patients with bacteremia: a comparison between three prospective cohorts

Authors: Vered Daitch, Yulia Akayzen, Yasmin Abu-Ghanem, Noa Eliakim-Raz, Mical Paul, Leonard Leibovici, Dafna Yahav

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2018

Login to get access

Abstract

The objective of this study was to explore whether the percentage of inappropriate empirical antibiotic treatment in patients with bacteremia changed over time and to understand the factors that brought on the change. Three prospective cohorts of patients with bacteremia in three different periods (January 1st, 1988 to December 31st, 1989; May 1st, 2004 to November 30, 2004; May 1st, 2010 to April 30, 2011) were compared. Analysis was performed on a total of 811 patients. In 2010–2011, 55.9% (76/136) of patients with bacteremia received inappropriate empirical treatment, compared with 34.5% (170/493) and 33.5% (55/164) in the first and second periods, respectively, in a significant upward trend (p = 0.001). Resistance to antibiotics increased significantly during the study period. The following variables were included in the multivariate analysis assessing risk factors for inappropriate empirical treatment: study period (third period) [odds ratio, OR = 2.766 (95% confidence interval, CI, 1.655–4.625)], gender (male) [OR = 1.511 (1.014–2.253)], pathogen carrying extended-spectrum beta-lactamases [OR = 10.426 (4.688–23.187)], multidrug-resistant Acinetobacter baumannii [OR = 5.428 (2.181–13.513)], and skin/soft infections [OR = 3.23 (1.148–9.084)]. A model excluding microbiological data included: gender (male) [OR = 1.648 (1.216–2.234)], study period (third period) [OR = 2.446 (1.653–3.620)], hospital-acquired infection [OR = 1.551 (1.060–2.270)], previous use of antibiotics [OR = 1.815 (1.247–2.642)], bedridden patient [OR = 2.019 (1.114–3.658)], and diabetes mellitus [OR = 1.620 (1.154–2.274)]. We have observed a worrisome increase in the rate of inappropriate empirical treatment of bacteremia. We need tools that will allow us better prediction of the pathogen and its susceptibilities during the first hours of managing a patient suspected of a severe bacterial infection.
Literature
1.
go back to reference Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y (2006) Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 50:1257–1262CrossRefPubMedPubMedCentral Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y (2006) Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 50:1257–1262CrossRefPubMedPubMedCentral
3.
go back to reference Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L (2010) Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 54:4851–4863CrossRefPubMedPubMedCentral Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L (2010) Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 54:4851–4863CrossRefPubMedPubMedCentral
4.
go back to reference Leibovici L, Samra Z, Konisberger H, Kalter-Leibovici O, Pitlik SD, Drucker M (1991) Bacteremia in adult diabetic patients. Diabetes Care 14(2):89–94CrossRefPubMed Leibovici L, Samra Z, Konisberger H, Kalter-Leibovici O, Pitlik SD, Drucker M (1991) Bacteremia in adult diabetic patients. Diabetes Care 14(2):89–94CrossRefPubMed
5.
go back to reference Leibovici L, Konisberger H, Pitlik SD, Samra Z, Drucker M (1992) Bacteremia and fungemia of unknown origin in adults. Clin Infect Dis 14(2):436–443CrossRefPubMed Leibovici L, Konisberger H, Pitlik SD, Samra Z, Drucker M (1992) Bacteremia and fungemia of unknown origin in adults. Clin Infect Dis 14(2):436–443CrossRefPubMed
6.
go back to reference Leibovici L, Konisberger H, Pitlik SD, Samra Z, Drucker M (1992) Patients at risk for inappropriate antibiotic treatment of bacteraemia. J Intern Med 231(4):371–374CrossRefPubMed Leibovici L, Konisberger H, Pitlik SD, Samra Z, Drucker M (1992) Patients at risk for inappropriate antibiotic treatment of bacteraemia. J Intern Med 231(4):371–374CrossRefPubMed
7.
go back to reference Paul M, Gafter-Gvili A, Leibovici L, Bishara J, Levy I, Yaniv I, Shalit I, Samra Z, Pitlik S, Konigsberger H, Weinberger M (2007) The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988–2004. Isr Med Assoc J 9(6):424–429PubMed Paul M, Gafter-Gvili A, Leibovici L, Bishara J, Levy I, Yaniv I, Shalit I, Samra Z, Pitlik S, Konigsberger H, Weinberger M (2007) The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988–2004. Isr Med Assoc J 9(6):424–429PubMed
8.
go back to reference Fraser A, Paul M, Almanasreh N, Tacconelli E, Frank U, Cauda R, Borok S, Cohen M, Andreassen S, Nielsen AD, Leibovici L; TREAT Study Group (2006) Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am J Med 119(11):970–976CrossRefPubMed Fraser A, Paul M, Almanasreh N, Tacconelli E, Frank U, Cauda R, Borok S, Cohen M, Andreassen S, Nielsen AD, Leibovici L; TREAT Study Group (2006) Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am J Med 119(11):970–976CrossRefPubMed
9.
go back to reference Endimiani A, Tamborini A, Luzzaro F, Lombardi G, Toniolo A (2003) A two-year analysis of risk factors and outcome in patients with bloodstream infection. Jpn J Infect Dis 56(1):1–7PubMed Endimiani A, Tamborini A, Luzzaro F, Lombardi G, Toniolo A (2003) A two-year analysis of risk factors and outcome in patients with bloodstream infection. Jpn J Infect Dis 56(1):1–7PubMed
10.
go back to reference Gasch O, Ayats J, Angeles Dominguez M, Tubau F, Liñares J, Peña C, Grau I, Pallarés R, Gudiol F, Ariza J, Pujol M (2011) Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection: secular trends over 19 years at a university hospital. Medicine (Baltimore) 90(5):319–327CrossRef Gasch O, Ayats J, Angeles Dominguez M, Tubau F, Liñares J, Peña C, Grau I, Pallarés R, Gudiol F, Ariza J, Pujol M (2011) Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection: secular trends over 19 years at a university hospital. Medicine (Baltimore) 90(5):319–327CrossRef
11.
go back to reference Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW (2005) Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 49:760–766CrossRefPubMedPubMedCentral Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW (2005) Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 49:760–766CrossRefPubMedPubMedCentral
12.
go back to reference Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D’Inzeo T, Fadda G, Cauda R, Spanu T (2007) Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 51:1987–1994CrossRefPubMedPubMedCentral Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D’Inzeo T, Fadda G, Cauda R, Spanu T (2007) Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 51:1987–1994CrossRefPubMedPubMedCentral
13.
go back to reference Suppli M, Aabenhus R, Harboe ZB, Andersen LP, Tvede M, Jensen JU (2011) Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobial therapy. Clin Microbiol Infect 17(7):1078–1083CrossRefPubMed Suppli M, Aabenhus R, Harboe ZB, Andersen LP, Tvede M, Jensen JU (2011) Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobial therapy. Clin Microbiol Infect 17(7):1078–1083CrossRefPubMed
14.
go back to reference Kahvecioglu D, Ramiah K, McMaughan D, Garfinkel S, McSorley VE, Nguyen QN, Yang M, Pugliese C, Mehr D, Phillips CD (2014) Multidrug-resistant organism infections in US nursing homes: a national study of prevalence, onset, and transmission across care settings, October 1, 2010–December 31, 2011. Infect Control Hosp Epidemiol 35:S48–S55CrossRefPubMed Kahvecioglu D, Ramiah K, McMaughan D, Garfinkel S, McSorley VE, Nguyen QN, Yang M, Pugliese C, Mehr D, Phillips CD (2014) Multidrug-resistant organism infections in US nursing homes: a national study of prevalence, onset, and transmission across care settings, October 1, 2010–December 31, 2011. Infect Control Hosp Epidemiol 35:S48–S55CrossRefPubMed
15.
go back to reference Sundvall PD, Stuart B, Davis M, Roderick P, Moore M (2015) Antibiotic use in the care home setting: a retrospective cohort study analysing routine data. BMC Geriatr 15:71CrossRefPubMedPubMedCentral Sundvall PD, Stuart B, Davis M, Roderick P, Moore M (2015) Antibiotic use in the care home setting: a retrospective cohort study analysing routine data. BMC Geriatr 15:71CrossRefPubMedPubMedCentral
16.
go back to reference Van Aken S, Lund N, Ahl J, Odenholt I, Tham J (2014) Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia. Scand J Infect Dis 46(11):753–762CrossRefPubMed Van Aken S, Lund N, Ahl J, Odenholt I, Tham J (2014) Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia. Scand J Infect Dis 46(11):753–762CrossRefPubMed
17.
go back to reference Denis B, Lafaurie M, Donay JL, Fontaine JP, Oksenhendler E, Raffoux E, Hennequin C, Allez M, Socie G, Maziers N, Porcher R, Molina JM (2015) Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study. Int J Infect Dis 39:1–6CrossRefPubMed Denis B, Lafaurie M, Donay JL, Fontaine JP, Oksenhendler E, Raffoux E, Hennequin C, Allez M, Socie G, Maziers N, Porcher R, Molina JM (2015) Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study. Int J Infect Dis 39:1–6CrossRefPubMed
18.
go back to reference Nguyen ML, Toye B, Kanji S, Zvonar R (2014) Risk factors for and outcomes of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species at a Canadian tertiary care hospital. Can J Hosp Pharm 68(2):136–143 Nguyen ML, Toye B, Kanji S, Zvonar R (2014) Risk factors for and outcomes of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species at a Canadian tertiary care hospital. Can J Hosp Pharm 68(2):136–143
19.
go back to reference Freeman JT, McBride SJ, Nisbet MS, Gamble GD, Williamson DA, Taylor SL, Holland DJ (2012) Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes. Int J Infect Dis 16(5):e371–e374CrossRefPubMed Freeman JT, McBride SJ, Nisbet MS, Gamble GD, Williamson DA, Taylor SL, Holland DJ (2012) Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes. Int J Infect Dis 16(5):e371–e374CrossRefPubMed
20.
go back to reference Nasa P, Juneja D, Singh O, Dang R, Singh A (2012) An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: incidence, risk factors and its impact on outcome. Eur J Intern Med 23(2):192–195CrossRefPubMed Nasa P, Juneja D, Singh O, Dang R, Singh A (2012) An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: incidence, risk factors and its impact on outcome. Eur J Intern Med 23(2):192–195CrossRefPubMed
21.
go back to reference Kariv G, Paul M, Shani V, Muchtar E, Leibovici L (2013) Benchmarking inappropriate empirical antibiotic treatment. Clin Microbiol Infect 19(7):629–633CrossRefPubMed Kariv G, Paul M, Shani V, Muchtar E, Leibovici L (2013) Benchmarking inappropriate empirical antibiotic treatment. Clin Microbiol Infect 19(7):629–633CrossRefPubMed
22.
go back to reference Dyar OJ, Pagani L, Pulcini C (2015) Strategies and challenges of antimicrobial stewardship in long-term care facilities. Clin Microbiol Infect 21(1):10–19CrossRefPubMed Dyar OJ, Pagani L, Pulcini C (2015) Strategies and challenges of antimicrobial stewardship in long-term care facilities. Clin Microbiol Infect 21(1):10–19CrossRefPubMed
23.
go back to reference Paul M, Nielsen AD, Goldberg E, Andreassen S, Tacconelli E, Almanasreh N, Frank U, Cauda R, Leibovici L; TREAT Study Group (2007) Prediction of specific pathogens in patients with sepsis: evaluation of TREAT, a computerized decision support system. J Antimicrob Chemother 59(6):1204–1207CrossRefPubMed Paul M, Nielsen AD, Goldberg E, Andreassen S, Tacconelli E, Almanasreh N, Frank U, Cauda R, Leibovici L; TREAT Study Group (2007) Prediction of specific pathogens in patients with sepsis: evaluation of TREAT, a computerized decision support system. J Antimicrob Chemother 59(6):1204–1207CrossRefPubMed
24.
go back to reference Paul M, Andreassen S, Tacconelli E, Nielsen AD, Almanasreh N, Frank U, Cauda R, Leibovici L; TREAT Study Group (2006) Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. J Antimicrob Chemother 58(6):1238–1245CrossRefPubMed Paul M, Andreassen S, Tacconelli E, Nielsen AD, Almanasreh N, Frank U, Cauda R, Leibovici L; TREAT Study Group (2006) Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. J Antimicrob Chemother 58(6):1238–1245CrossRefPubMed
Metadata
Title
Secular trends in the appropriateness of empirical antibiotic treatment in patients with bacteremia: a comparison between three prospective cohorts
Authors
Vered Daitch
Yulia Akayzen
Yasmin Abu-Ghanem
Noa Eliakim-Raz
Mical Paul
Leonard Leibovici
Dafna Yahav
Publication date
01-03-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2018
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-018-3190-1
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.